Brief: Vertex Pharmaceuticals Exec Says Cystic Fibrosis Portfolio Has About 9% Exposure To Medicare And About 23% Exposure To Medicaid - Goldman Sachs Conference
10/06/2025 20:17
Vertex Pharmaceuticals Inc VRTX.O: VERTEX PHARMACEUTICALS EXEC SAYS CYSTIC FIBROSIS PORTFOLIO HAS ABOUT 9% EXPOSURE TO MEDICARE AND ABOUT 23% EXPOSURE TO MEDICAID - GOLDMAN SACHS CONFERENCE VERTEX PHARMACEUTICALS EXEC SAYS LARGER HOSPITALS HAVE ADDED JOURNAVX TO THEIR FORMULARY AND EXPECT MORE IN H2 2025 Source text: [ID:] Further company coverage: VRTX.O
Recent news on Vertex Pharmaceuticals Incorporated
See all newsBrief: Vertex Appoints Daniel Brennan To Its Board Of Directors
US RESEARCH ROUNDUP- Allstate, Autozone, Vertex Pharmaceuticals
U.S. STOCKS ON THE MOVE-Greenland Mines, GameStop, Shopify
Vertex rises after kidney disease drug shows promise in mid-stage study
Brief: Vertex Pharmaceuticals Incorporated Says Inaxaplin Reduces UACR By -42.7% At Week 13 In AMKD With Modest Proteinuria